Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation

Kinetics of recovery of dendritic cell subsets after reduced-intensity conditioning allogeneic stem cell transplantation and clinical outcome

“…Mohty et al recently studied a series of patients undergoing allo-RIC and reported a relationship between plasmacytoid DC counts and TRM; like us, they did not find any correlation between high plasmacytoid DC counts and lower risk of disease progression or relapse. 33 The results from this series and those from Mohty et al are in line with the findings of Waller et al, who suggested that higher numbers of plasmacytoid DC were, in fact, associated with a higher incidence of relapse after myeloablative transplantation. 34 In this sense, it is known that plasmacytoid DC polarize T cells toward a Th2 phenotype, which reduces graft-versushost reactions.…”

“…In conclusion, this study confirms the clinical importance of DC recovery after allo-RIC, 33 and shows that the recently identified subset of CD16 + DC might be key functional anti-infectious and anti-tumor cells in patients undergoing this treatment.…”

Immune reconstitution after allogeneic stem cell transplantation with reduced-intensity conditioning regimens

“…The authors did not find significant correlation between DCs or T-cell mixed chimerism and GvHD or relapse. In contrast to these results, Mohty et al 53 observed that high DC2 recovery profile at 3 months after RIC-SCT was associated with improved survival and a lower risk for late infection. Similarly, in another study, a low DCs count at the time of engraftment was associated with higher risk for death, relapse and acute GvHD after MAC-SCT and RIC-SCT.…”

Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning

“…Chimerism levels among granulocytes have been poor predictors for HCT outcomes, but further studies are needed to evaluate the efficacy of chimerism monitoring among cell subtypes enriched for the phenotype of the malignant cells. In addition, the impact of donor chimerism levels among other cell sub-types (such as dendritic cells, 87,88 Langerhans cells, 89 plasmacytoid dendritic cells, 90 mesenchymal cells, 91 or regulatory T-cells 92 ) on HCT outcomes after nonmyemoablative conditioning deserves further investigation. Finally, in patients with hematological relapse after HCT, assessing the origin of both malignant cells and T-cells might assist in determining the best therapeutic options.…”